keyword
MENU ▼
Read by QxMD icon Read
search

Who ovarian cancer

keyword
https://www.readbyqxmd.com/read/29667217/secondary-prostate-cancer-screening-outcomes-by-race-in-the-prostate-lung-colorectal-and-ovarian-plco-screening-trial
#1
Eric A Miller, Paul F Pinsky, Amanda Black, Gerald L Andriole, Dudith Pierre-Victor
BACKGROUND: Despite disparities in prostate cancer incidence and mortality rates between black and white men, there is still insufficient data available to assess potential differences in the benefits and harms of prostate cancer screening by race. Although the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial is underpowered to detect a difference by race in prostate-cancer specific mortality, because of the large study size, there are still sufficient numbers to examine secondary screening outcomes...
April 17, 2018: Prostate
https://www.readbyqxmd.com/read/29667103/a-healthy-lifestyle-index-and-its-association-with-risk-of-breast-endometrial-and-ovarian-cancer-among-canadian-women
#2
Rhonda Arthur, Victoria A Kirsh, Nancy Kreiger, Thomas Rohan
PURPOSE: Several modifiable risk factors have been associated with risk of female cancers, but there is limited data regarding their combined effect on risk among Canadian women. Therefore, we assessed the joint association of modifiable risk factors, using a healthy lifestyle index (HLI) score, with risk of specific reproductive cancers. METHOD: This study included a subcohort of 3,185 of the 39,618 women, who participated in the Canadian Study of Diet, Lifestyle, and Health, and in whom 410, 177, and 100 postmenopausal breast, endometrial, and ovarian cancers, respectively, were ascertained...
April 17, 2018: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/29665859/morphology-and-genomic-hallmarks-of-breast-tumours-developed-by-atm-deleterious-variant-carriers
#3
Anne-Laure Renault, Noura Mebirouk, Laetitia Fuhrmann, Guillaume Bataillon, Eve Cavaciuti, Dorothée Le Gal, Elodie Girard, Tatiana Popova, Philippe La Rosa, Juana Beauvallet, Séverine Eon-Marchais, Marie-Gabrielle Dondon, Catherine Dubois d'Enghien, Anthony Laugé, Walid Chemlali, Virginie Raynal, Martine Labbé, Ivan Bièche, Sylvain Baulande, Jacques-Olivier Bay, Pascaline Berthet, Olivier Caron, Bruno Buecher, Laurence Faivre, Marc Fresnay, Marion Gauthier-Villars, Paul Gesta, Nicolas Janin, Sophie Lejeune, Christine Maugard, Sébastien Moutton, Laurence Venat-Bouvet, Hélène Zattara, Jean-Pierre Fricker, Laurence Gladieff, Isabelle Coupier, Georgia Chenevix-Trench, Janet Hall, Anne Vincent-Salomon, Dominique Stoppa-Lyonnet, Nadine Andrieu, Fabienne Lesueur
BACKGROUND: The ataxia telangiectasia mutated (ATM) gene is a moderate-risk breast cancer susceptibility gene; germline loss-of-function variants are found in up to 3% of hereditary breast and ovarian cancer (HBOC) families who undergo genetic testing. So far, no clear histopathological and molecular features of breast tumours occurring in ATM deleterious variant carriers have been described, but identification of an ATM-associated tumour signature may help in patient management. METHODS: To characterise hallmarks of ATM-associated tumours, we performed systematic pathology review of tumours from 21 participants from ataxia-telangiectasia families and 18 participants from HBOC families, as well as copy number profiling on a subset of 23 tumours...
April 17, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29664846/a-comprehensive-program-enabling-effective-delivery-of-regional-genetic-counseling
#4
Jubilee Brown, Aly Athens, David L Tait, Erin K Crane, Robert V Higgins, R Wendel Naumann, Lejla Hadzikadic Gusic, Lisa Amacker-North
OBJECTIVES: The aim of this study was to demonstrate the utility of a comprehensive program involving management-based evidence, telemedicine, and patient navigation to provide genetic counseling services for patients with ovarian and breast cancer across a geographically large health care system. METHODS: We identified all patients with newly diagnosed ovarian and breast cancer in our health care system from January 2013 to December 2015 through the cancer registry...
April 16, 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29664840/malignant-ascites-validation-of-a-novel-ascites-symptom-mini-scale-for-use-in-patients-with-ovarian-cancer
#5
Ram Eitan, Oded Raban, Daliah Tsoref, Ariella Jakobson-Setton, Gad Sabah, Lina Salman, Effi Yeoshua, Avi Ben-Haroush
BACKGROUND: Ascites is a common finding in patients with ovarian cancer. Paracentesis is a relatively simple, safe, and effective procedure for draining fluid from the peritoneum, but valid quality-of-life tools are needed to determine its subjective value for alleviating symptoms and improving patient quality of life. The objective of this study was to prospectively evaluate the performance of a novel Ascites Symptom Mini-Scale (ASmS) and compare it with a previously available questionnaire...
April 16, 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29662660/clinical-outcomes-of-women-with-ovarian-metastases-of-colorectal-cancer-treated-with-oophorectomy-with-respect-to-their-somatic-mutation-profiles
#6
Yoshiko Mori, Akihiro Nyuya, Kazuya Yasui, Toshiaki Toshima, Takashi Kawai, Fumitaka Taniguchi, Keisuke Kimura, Ryo Inada, Masahiko Nishizaki, Junko Haraga, Keiichiro Nakamura, Yuzo Umeda, Hiroyuki Kishimoto, Toshiyoshi Fujiwara, Yosuke Katata, Yoshiyuki Yamaguchi, Takeshi Nagasaka
We clarified the clinical prevalence of ovarian metastases from colorectal cancers (CRCs) in 296 female patients with CRC and evaluated clinical outcomes with relation to their mutational profiles, such as BRAF/KRAS mutation and microsatellite instability (MSI) status. The female CRCs were categorised into three subsets: CRCs with ovarian metastases [6.4% ( n = 19), 5-year overall survival (OS) = 24.7%], CRCs with extra-ovarian metastases only [32.4% ( n = 96), 5-year OS = 34.5%] and CRCs without any recurrence or metastasis [61...
March 27, 2018: Oncotarget
https://www.readbyqxmd.com/read/29662617/premature-ovarian-aging-in-brca-carriers-a-prototype-of-systemic-precocious-aging
#7
Irit Ben-Aharon, Mattan Levi, David Margel, Rinat Yerushalmi, Shulamith Rizel, Shlomit Perry, Eran Sharon, Noa Hasky, Ronit Abir, Benny Fisch, Ana Tobar, Ruth Shalgi, Salomon Marcello Stemmer
Purpose: Though former evidence implies a correlation of breast cancer susceptibility gene ( BRCA ) mutation with reduced ovarian reserve, the data is yet inconsistent. Our aim was to investigate biomarkers of ovarian aging in a cohort of young healthy carriers of the BRCA mutation. We hypothesized that the role played by BRCA genes in aging pathways is not exclusive to the ovary. Experimental Design: Healthy female BRCA carriers, 40 years or younger and healthy male BRCA carriers, 50 years or younger, were enrolled in the study...
March 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29661801/anti-ca15-3-and-anti-ca125-antibodies-and-ovarian-cancer-risk-results-from-the-epic-cohort
#8
Daniel W Cramer, Raina N Fichorova, Kathryn L Terry, Hidemi S Yamamoto, Allison F Vitonis, Eva Ardanaz, Dagfinn Aune, Heiner Boeing, Jenny Brändstedt, Marie-Christine Boutron-Ruault, Maria-Dolores Chirlaque, Miren Dorronsoro, Laure Dossus, Eric J Duell, Inger T Gram, Marc J Gunter, Louise Hansen, Annika Idahl, Theron Johnson, Kay-Tee Khaw, Vittorio Korgh, Marina Kvaskoff, Amalia Mattiello, Giuseppe Matullo, Melissa A Merritt, Björn Nodin, N Charlotte Onland-Moret, Philippos Orfanos, Domenico Palli, Eleni Peppa, J Ramón Quirós, Maria-José Sànchez-Pérez, Gianluca Severi, Ruth C Travis, Antonia Trichopoulou, Rosario Tumino, Elisabete Weiderpass, Renée Turzanski Fortner, Rudolf Kaaks
BACKGROUND: Neoplastic and non-neoplastic events may raise levels of mucins, CA15.3 and CA125, and generate antibodies against them; but their impact on epithelial ovarian cancer (EOC) risk has not been fully defined. METHODS: CA15.3, CA125, and IgG1 antibodies against them were measured in 806 women who developed EOC and 1,927 matched controls from the European Prospective Investigation of Nutrition and Cancer. Associations between epidemiologic factors and anti-mucin antibodies were evaluated using generalized linear models; EOC risks associated with anti-mucin antibodies, by themselves or in combination with respective antigens, were evaluated using conditional logistic regression...
April 16, 2018: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/29661043/risks-and-consequences-of-travel-burden-on-prophylactic-granulocyte-colony-stimulating-factor-administration-and-incidence-of-febrile-neutropenia-in-an-aged-medicare-population
#9
J Mark Stephens, Mark Bensink, Charles Bowers, Christopher S Hollenbeak
OBJECTIVE: Granulocyte colony-stimulating factors (G-CSFs) decrease the incidence of febrile neutropenia (FN) in patients receiving myelosuppressive chemotherapy. In this study, we examined the impact patient travel burden has on administration of prophylactic G-CSFs and the subsequent impact on FN incidence. METHODS: Medicare claims data were used to identify a cohort of beneficiaries age 65+ with non-myeloid cancers at high risk for FN between January 2012 and December 2014...
April 17, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29659826/association-between-ambient-air-pollution-and-pregnancy-rate-in-women-who-underwent-ivf
#10
S A Choe, Y B Jun, W S Lee, T K Yoon, S Y Kim
STUDY QUESTION: Are the concentrations of five criteria air pollutants associated with probabilities of biochemical pregnancy loss and intrauterine pregnancy in women? SUMMARY ANSWER: Increased concentrations of ambient particulate matter (PM10), nitrogen dioxide (NO2), carbon monoxide (CO) during controlled ovarian stimulation (COS) and after embryo transfer were associated with a decreased probability of intrauterine pregnancy. WHAT IS KNOWN ALREADY: Exposure to high ambient air pollution was suggested to be associated with low fertility and high early pregnancy loss in women...
April 5, 2018: Human Reproduction
https://www.readbyqxmd.com/read/29659587/can-chimerism-explain-breast-ovarian-cancers-in-brca-non-carriers-from-brca-positive-families
#11
Rachel Mitchell, Lela Buckingham, Melody Cobleigh, Jacob Rotmensch, Kelly Burgess, Lydia Usha
Hereditary breast and ovarian cancer syndrome (HBOC) is most frequently caused by mutations in BRCA1 or BRCA2 (in short, BRCA) genes. The incidence of hereditary breast and ovarian cancer in relatives of BRCA mutation carriers who test negative for the familial mutation (non-carriers) may be increased. However, the data is controversial, and at this time, these individuals are recommended the same cancer surveillance as general population. One possible explanation for BRCA phenocopies (close relatives of BRCA carriers who have developed cancer consistent with HBOC but tested negative for a familial mutation) is natural chimerism where lack of detectable mutation in blood may not rule out the presence of the mutation in the other tissues...
2018: PloS One
https://www.readbyqxmd.com/read/29658435/combined-immunotherapy-ok-432-il-2-with-chemotherapy-decrease-the-recurrence-rate-in-advanced-ovarian-cancer
#12
Yi-Lun Wang, Hsiu-Huei Peng, Sheng-Yuan Su, Cheng-Tao Lin
OBJECTIVE: In advanced ovarian cancer, traditional therapy included debulking surgery and postoperative chemotherapy. We proposed immunochemotherapy (IMCT) combined with picibanil (OK-432), interleukin-2 (IL-2), and traditional platinum- and taxol-based chemotherapy as a better treatment option for advanced ovarian cancer. METHODS: We retrospectively reviewed the medical records of 51 patients with advanced ovarian cancer between 2007 and 2015 at Chang Gung Memorial Hospital Linkou Medical Center, including 26 patients who were treated with OK-432, IL-2, and platinum- and taxol-based chemotherapy (IMCT group) after debulking surgery; another 25 were treated with traditional platinum- and taxol-based chemotherapy (traditional chemotherapy group) after debulking surgery...
January 1, 2018: Reproductive Sciences
https://www.readbyqxmd.com/read/29656331/survey-of-pelvic-reconstructive-surgeons-on-performance-of-opportunistic-salpingectomy-at-the-time-of-pelvic-organ-prolapse-repair
#13
Daisy B Hassani, Jeffrey M Mangel, Sangeeta T Mahajan, Adonis K Hijaz, Sherif El-Nashar, David Sheyn
INTRODUCTION AND HYPOTHESIS: Opportunistic salpingectomy (OS) at the time of benign hysterectomy has recently emerged as a potential primary preventive modality for ovarian cancer. Our objective was to determine whether the reported rate of OS at the time of prolapse surgery is similar to the rate of OS at the time of gynecologic surgery for non-prolapse indications. METHODS: An anonymous online survey was sent to the Society of Gynecologic Surgery members. Responses were divided into surgeons who did and did not perform OS at the time of prolapse repair...
April 14, 2018: International Urogynecology Journal
https://www.readbyqxmd.com/read/29650751/fda-approval-summary-niraparib-for-the-maintenance-treatment-of-patients-with-recurrent-ovarian-cancer-in-response-to-platinum-based-chemotherapy
#14
Gwynn Ison, Lynn J Howie, Laleh Amiri-Kordestani, Lijun Zhang, Shenghui Tang, Rajeshwari Sridhara, Vadryn Pierre, Rosane Charlab, Anuradha Ramamoorthy, Pengfei Song, Fang Li, Jingyu Yu, Wimolnut Manheng, Todd R Palmby, Soma Ghosh, Hisani N Horne, Eunice Y Lee, Reena Philip, Kaushalkumar Dave, Xiao Hong Chen, Sharon L Kelly, Kumar G Janoria, Anamitro Banerjee, Okponanabofa Eradiri, Jeannette Dinin, Kirsten B Goldberg, William F Pierce, Amna Ibrahim, Paul G Kluetz, Gideon M Blumenthal, Julia A Beaver, Richard Pazdur
The Food and Drug Administration approved niraparib, a poly ADP ribose polymerase (PARP) inhibitor, on March 27, 2017, for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy. Approval was based on data from the NOVA trial comparing niraparib with placebo in two independent cohorts, based on germline BRCA mutation status (gBRCAm vs. non-gBRCAm). Progression-free survival (PFS) in each cohort was the primary endpoint...
April 12, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29644780/support-needs-of-couples-with-hereditary-breast-and-ovarian-cancer-during-reproductive-decision-making
#15
J J G Gietel-Habets, C E M de Die-Smulders, I A P Derks-Smeets, A Tibben, V C G Tjan-Heijnen, R van Golde, E Gomez-Garcia, L A D M van Osch
OBJECTIVE: Reproductive decision-making for couples with hereditary breast and ovarian cancer (HBOC) is complex and can result in decisional conflict or -regret. This study investigated couples' support needs and aimed to identify vulnerable couples. Ultimately we should strive to develop a clear standard of care guideline regarding reproductive decision-support. METHODS: Mixed methods were used for data collection. A focus group study was conducted among 18 couples (N=35) with HBOC who had made a reproductive decision after reproductive counselling...
April 12, 2018: Psycho-oncology
https://www.readbyqxmd.com/read/29644766/fear-of-recurrence-among-older-breast-ovarian-endometrial-and-colorectal-cancer-survivors-findings-from-the-whi-lilac-study
#16
Jessica L Krok-Schoen, Michelle J Naughton, Brittany M Bernardo, Gregory S Young, Electra D Paskett
OBJECTIVE: To examine the prevalence of and factors associated with fear of recurrence (FCR) following treatment for breast, ovarian, endometrial, and colorectal cancer among older women. METHODS: Participants were enrolled in the Women's Health Initiative WHI Life and Longevity After Cancer (LILAC) study. Descriptive statistics and multivariate logistic regression models were used to assess the association of demographic, clinical, and quality of life variables with survivors' FCR, dichotomized as <14 (low) or ≥14 (high) using the Cancer Worry Scale...
April 12, 2018: Psycho-oncology
https://www.readbyqxmd.com/read/29644491/update-on-parp-inhibitors-in-breast-cancer
#17
REVIEW
Alexandra S Zimmer, Mitchell Gillard, Stanley Lipkowitz, Jung-Min Lee
The single agent activity of PARP inhibitors (PARPi) in germline BRCA mutated (gBRCAm) breast and ovarian cancer suggests untapped potential for this new class of drug in breast cancer. The US Food and Drug Administration has approved three PARPi (olaparib, rucaparib, and niraparib) so far to treat certain ovarian cancers, including those with gBRCAm and olaparib for treatment of gBRCAm breast cancers. Several PARPi are now under clinical development for breast cancer in the various treatment settings. Recently, two phase III trials of olaparib (OlympiaD) and talazoparib (EMBRACA) demonstrated 3-month progression-free survival improvement with PARPi compared to physician's choice single agent chemotherapy in metastatic gBRCAm breast cancer...
April 11, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29627127/the-action-of-estrogens-and-progestogens-in-the-young-female-breast
#18
Irene Zolfaroli, Juan J Tarín, Antonio Cano
Evidence from different sources sustains a pro-oncogenic role of hormones, estrogens and progestogens, on the breast. The issue is of interest for young women, who are exposed to the hormonal changes imposed by the ovarian cycle and, often, take hormones with contraceptive purposes. Experimental and clinical studies show that both estrogens and progesterone are involved in mammary development during puberty and lactation, the changes being observed across mammalian species, including humans. Estrogen receptors, and more particularly the alpha isoform, participate in molecular processes of stem cells differentiation and epithelial proliferation through paracrine actions implicating growth factors...
March 28, 2018: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/29624506/laparoscopic-assessment-to-determine-the-likelihood-of-achieving-optimal-cytoreduction-in-patients-undergoing-primary-debulking-surgery-for-ovarian-fallopian-tube-or-primary-peritoneal-cancer
#19
Vaagn Andikyan, Annie Kim, Herbert F Gretz, Konstantin Zakashansky, Monica Prasad-Hayes, Ann-Marie Beddoe, Peter Dottino, John Mandeli, Linus Chuang
OBJECTIVE: The objective of this study was to evaluate the safety and efficacy of laparoscopic assessment to determine the likelihood of achieving optimal cytoreduction (OC) in patients undergoing primary debulking surgery (PDS) for ovarian cancer. METHODS: All patients who underwent diagnostic laparoscopy and PDS at our institution from January 2008 to December 2013 were identified. We determined the likelihood of achieving optimal cytoreduction by laparoscopic assessment based on tumor site, pattern of spread, and disease burden...
April 5, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29623583/pathology-findings-and-clinical-outcomes-after-risk-reduction-salpingo-oophorectomy-in-brca-mutation-carriers-a-multicenter-spanish-study
#20
L Minig, S Cabrera, R Oliver, A Couso, M J Rubio, S Iacoponi, M B Martin-Salamanca, S Carballo-Rastrilla, J M Cádenas-Rebollo, A García-Garcia, B Gil-Ibáñez, M J Juan-Fita, M G Patrono
OBJECTIVE: To determine the incidence of serous tubal intraepithelial carcinoma (STIC) after risk reduction salpingo-oophorectomy(RRSO), and to describe oncological outcomes after RRSO. MATERIALS AND METHODS: BRCA pathogenic mutation carriers who had undergone an RRSO were evaluated in this retrospective multicenter observational study. Patients were only included when fallopian tubes were analyzed following the protocol for Sectioning and Extensively Examining the FIMbria (SEE-FIM)...
April 5, 2018: Clinical & Translational Oncology
keyword
keyword
100582
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"